retatrutide phase 2 trial type 2 diabetes 🚨Breaking: Retatrutide's first 3 T2D data just dropped. ▸ A1C: −2.0% at 40 weeks ▸ Weight: −36.6 lbs (−16.8%) at 12 mg ▸ No weight loss plateau — curve still descending Retatrutide Phase 2: Type 2

The Research History in One Sentence Ipamorelin has established receptor pharmacology and limited human research, but the controlled proof of concept study did not demonstrate significant differences in its main efficacy analyses and did not lead to an identified UK authorisation

1S46318N)

Secondary outcomes included the proportion of patients achieving complete resolution of rectal bleeding, reduction in clinical signs of inflammation and prolapse, and overall physician-assessed improvement

Your body is constantly communicating

For the first time in 2024, the American Diabetes Association recognized combination therapy for treating Type 2 diabetes